Aortic Stent Grafts Market Size, Share, Growth, and Industry Analysis, By Types (Endovascular Aneurysm Repair(EVAR),Abdominal Aortic Aneurysm Repair,Other) , Applications (Hospitals,Clinics,Ambulatory Surgical Centers) and Regional Insights and Forecast to 2033

Aortic Stent Grafts Market Size

The Aortic Stent Grafts Market was valued at USD 2,194.62 million in 2024 and is expected to reach USD 2,326.3 million in 2025, eventually growing to USD 3,716.1 million by 2033, reflecting a CAGR of 6% over the forecast period from 2025 to 2033.

The U.S. Aortic Stent Grafts Market is poised for steady growth, driven by advancements in endovascular procedures, a rising prevalence of aortic diseases, and increasing adoption of minimally invasive treatments. Strong healthcare infrastructure supports market expansion.

The aortic stent grafts market is a critical segment within the medical devices industry, focusing on the treatment of aortic aneurysms through minimally invasive procedures. Aortic stent grafts are specialized devices designed to reinforce the weakened walls of the aorta, thereby preventing rupture and subsequent life-threatening complications. The increasing prevalence of aortic aneurysms, particularly among the aging population, has significantly contributed to the demand for these devices. In 2023, the global market for aortic stent grafts was valued at approximately USD 2.5 billion, with projections indicating a steady growth trajectory in the coming years. This growth is driven by advancements in endovascular repair techniques, which offer less invasive alternatives to traditional open surgical procedures. The market is characterized by a diverse range of products tailored to address various anatomical challenges associated with aortic aneurysms, including both abdominal and thoracic regions. Key players in the industry are continually innovating to enhance device flexibility, durability, and ease of deployment, thereby improving patient outcomes. 

Aortic Stent Grafts Market Trends

The aortic stent grafts market is witnessing several notable trends that are shaping its evolution. One significant trend is the increasing preference for minimally invasive endovascular aneurysm repair (EVAR) procedures over traditional open surgeries. This shift is attributed to the reduced recovery times, lower complication rates, and improved patient comfort associated with EVAR. In recent years, over 70% of aortic aneurysm repairs in developed regions have been performed using EVAR, highlighting its growing adoption. Consequently, there has been a surge in the development and adoption of advanced stent graft technologies designed to accommodate a wider range of patient anatomies. Another trend is the growing utilization of branched and fenestrated stent grafts, which enable the treatment of complex aortic aneurysms involving branch vessels. These specialized devices have expanded the therapeutic options for patients with challenging anatomies, with fenestrated stent graft procedures accounting for approximately 10-15% of all EVAR cases. Furthermore, the integration of imaging technologies and the development of customized stent graft solutions are gaining traction, allowing for more precise planning and execution of procedures. Studies indicate that the use of advanced imaging in EVAR has contributed to a 20-30% reduction in procedural complications. Additionally, there is an increasing focus on the development of stent grafts with improved materials and designs that offer enhanced durability and flexibility, addressing issues related to device fatigue and migration. Some newer stent grafts have demonstrated a 95% patency rate at five years, significantly reducing the need for reinterventions. As the global population continues to age, the prevalence of aortic aneurysms is expected to rise, with over 200,000 new cases diagnosed annually worldwide, further driving the demand for innovative stent graft solutions. 

Aortic Stent Grafts Market Dynamics

The dynamics of the aortic stent grafts market are influenced by a combination of drivers, restraints, opportunities, and challenges that collectively shape its trajectory. A primary driver of market growth is the increasing incidence of aortic aneurysms, with over 200,000 new cases diagnosed annually worldwide, particularly among the elderly population. Studies indicate that approximately 75% of abdominal aortic aneurysms (AAA) occur in individuals over the age of 65, underscoring the need for effective treatment options. The preference for minimally invasive procedures, such as endovascular aneurysm repair (EVAR), has surged, with EVAR accounting for nearly 70% of all aortic aneurysm repairs in developed countries due to benefits like reduced hospital stays and quicker recovery times. Technological advancements have led to the development of next-generation stent grafts with enhanced flexibility and durability, with some models demonstrating a 95% patency rate at five years, catering to a broader range of patient anatomies. Additionally, increased awareness and screening programs have facilitated early detection, with screening initiatives identifying undiagnosed aneurysms in approximately 1-2% of individuals over 65, thereby expanding the patient pool eligible for stent graft interventions.

Drivers of Market Growth

A primary driver of market growth is the increasing incidence of aortic aneurysms, particularly among the elderly population. Despite these positive drivers, the market faces certain restraints. The high cost of aortic stent graft procedures, which can range between $25,000 and $50,000 per patient, poses a significant financial burden, particularly for those without adequate insurance coverage. Reimbursement challenges vary by region, with some healthcare systems covering only partial costs, limiting accessibility. Clinical complications, such as endoleaks occurring in approximately 10-25% of EVAR cases and device migration in 1-3% of patients, can deter both patients and healthcare providers from opting for stent graft solutions. 

Market Restraints

However, the market presents several opportunities for expansion. Emerging economies, where healthcare infrastructure is rapidly improving, offer untapped potential, with regions like Asia-Pacific witnessing an increase in aortic aneurysm diagnosis and treatment rates. The development of customized and patient-specific stent graft solutions is gaining momentum, particularly for complex cases, with fenestrated and branched stent grafts now accounting for around 15% of EVAR procedures. Collaborations between medical device companies and research institutions are driving innovation, with global investment in vascular device R&D exceeding $1 billion annually. Additionally, the integration of advanced imaging and navigation technologies has led to a 20-30% reduction in procedural complications, improving patient outcomes and driving market growth.

Market Opportunities

Despite these opportunities, the market is not without challenges. The complexity of aortic stent graft procedures necessitates specialized training for healthcare providers, and a shortage of skilled professionals remains a concern, particularly in developing regions. Economic constraints in low-income and middle-income countries limit the adoption of these devices, as treatment costs remain unaffordable for a large portion of the population. Furthermore, competition from alternative treatment modalities, such as open surgical repair, persists, with open surgery still being performed in approximately 30% of aortic aneurysm cases where EVAR is deemed unsuitable. 

Market Challenges

The aortic stent graft market faces several challenges that could affect its growth trajectory. One of the key challenges is the complexity of the procedures, which require specialized training for healthcare providers. A lack of skilled professionals, particularly in emerging economies, can impede the widespread adoption of stent graft technologies. It’s estimated that less than 30% of healthcare professionals in some regions have received comprehensive training in advanced endovascular techniques, limiting the number of procedures performed. Additionally, the high cost of stent graft procedures, which can range from $25,000 to $50,000, may restrict their adoption, especially in low-income and middle-income countries. In fact, a significant portion of the global population lacks access to affordable healthcare, with over 40% of people in lower-income countries not receiving timely treatment for aortic aneurysms.

Furthermore, competition from alternative treatment options, such as open surgical repair, continues to pose a challenge. Open surgery is still performed in around 30% of cases where endovascular aneurysm repair (EVAR) is not suitable, particularly in patients with complex aneurysm anatomies. The complexity, risk, and longer recovery times associated with open surgery may deter patients and healthcare providers from opting for newer technologies like stent grafts, despite the latter's advantages. Addressing these challenges requires a multifaceted approach that includes increasing educational programs for healthcare providers, improving cost management through government and insurance support, and fostering continuous innovation to improve device affordability and efficacy.

Segmentation Analysis

The aortic stent grafts market is segmented based on type and application, each encompassing distinct categories that cater to specific clinical needs. In terms of type, the market includes bifurcated, straight, fenestrated, and branched stent grafts, each designed to address different aortic aneurysm anatomies. Bifurcated stent grafts are the most widely used, accounting for over 60% of all EVAR procedures, due to their effectiveness in treating abdominal aortic aneurysms (AAA) and their ability to bypass the iliac arteries. Straight stent grafts are also commonly used in abdominal and thoracic aneurysms and make up around 25% of the market share. Fenestrated and branched stent grafts, which are used to treat complex aneurysms involving branch vessels, have grown significantly in recent years, with these devices accounting for approximately 15% of the total EVAR procedures performed. Fenestrated stent grafts alone represent roughly 8-10% of the total EVAR market, with the demand for these devices increasing due to their ability to treat patients with challenging anatomies that traditional stent grafts cannot address.

By Type

• Endovascular Aneurysm Repair (EVAR): Endovascular Aneurysm Repair (EVAR) is a minimally invasive procedure used to treat abdominal aortic aneurysms (AAAs). In this technique, a stent graft is inserted through small incisions in the groin and guided to the site of the aneurysm, where it reinforces the weakened aortic wall. EVAR has become the preferred method for AAA repair due to its reduced recovery time and lower perioperative morbidity compared to open surgical repair. The global market for aortic stent grafts, which includes devices used in EVAR procedures, was valued at approximately USD 3.12 billion in 2023.
• The increasing prevalence of AAAs, particularly among the aging population, has driven the demand for EVAR procedures. Additionally, advancements in stent graft technology, such as improved materials and designs, have enhanced the efficacy and safety of EVAR, further propelling its adoption in clinical practice.
• Abdominal Aortic Aneurysm Repair: Abdominal Aortic Aneurysm (AAA) repair encompasses both endovascular and open surgical approaches to treat aneurysms located in the abdominal segment of the aorta. While EVAR is minimally invasive, open surgical repair involves a larger incision to directly access the aneurysm and replace the affected aortic segment with a synthetic graft. Despite the invasiveness of open repair, it remains a viable option for patients with anatomies unsuitable for EVAR. The market for abdominal aortic stent grafts, specifically designed for EVAR procedures, has seen significant growth.
• Other Types: Beyond standard EVAR and traditional open surgical repair, the field of aortic aneurysm treatment has expanded to include specialized procedures and devices tailored to complex aneurysm anatomies. Thoracic Endovascular Aneurysm Repair (TEVAR) is one such procedure used to treat aneurysms in the thoracic aorta. The market for thoracic aortic stent grafts has been growing, driven by the increasing recognition of thoracic aortic aneurysms and the benefits of minimally invasive repair techniques. Additionally, branched and fenestrated stent grafts have been developed to accommodate aneurysms involving branch vessels, allowing for endovascular repair in patients who were previously considered unsuitable for standard EVAR or TEVAR. The global branched stent grafts market was valued at USD 280.9 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 7.9% from 2021 to 2028.

By Application

• Hospitals: Hospitals represent the primary setting for aortic stent graft procedures, including both EVAR and TEVAR. The comprehensive infrastructure, availability of advanced imaging modalities, and presence of multidisciplinary teams make hospitals well-equipped to handle the complexities associated with aortic aneurysm repairs. In 2023, the global aortic stent grafts market was valued at approximately USD 3.12 billion, with hospitals accounting for a significant portion of this market share.
• Clinics: While less common than hospitals, certain specialized clinics have the capability to perform aortic stent graft procedures, particularly in regions with well-established outpatient surgical infrastructures. These clinics often focus on providing minimally invasive treatments and may cater to patients requiring elective EVAR procedures. The appeal of clinics lies in their ability to offer a more personalized patient experience, often with reduced waiting times and a streamlined care process. However, the limited resources compared to hospitals may restrict their capacity to manage complex cases or emergencies. As a result, clinics typically handle straightforward cases with a low risk of complications, referring more complex scenarios to larger hospital centers.
• Ambulatory Surgical Centers: Ambulatory Surgical Centers (ASCs) have emerged as alternative venues for performing certain vascular procedures, including EVAR, especially in healthcare systems emphasizing cost-efficiency and patient convenience. ASCs offer a less intimidating environment than traditional hospitals and can provide high-quality care for selected patients undergoing elective procedures. The global aortic stent grafts market, which includes devices used in various settings such as ASCs, was valued at approximately USD 3.12 billion in 2023.
• The suitability of ASCs for aortic stent graft procedures depends on factors such as patient selection, the complexity of the aneurysm, and the availability of necessary postoperative care. While ASCs can offer advantages in terms of reduced costs and increased patient satisfaction, they must ensure stringent protocols are in place to handle any complications that may arise during or after the procedure.

Regional Outlook

The global Aortic Stent Grafts market exhibits significant regional variations, driven by factors such as healthcare infrastructure, prevalence of aortic aneurysms, and advancements in medical technology. North America, Europe, Asia-Pacific, and the Middle East & Africa contribute significantly to market growth, each characterized by unique dynamics.

North America

holds the largest market share, accounting for over 40% of the global aortic stent graft market. This is primarily due to the region's advanced healthcare infrastructure, high prevalence of aortic aneurysms, and early adoption of minimally invasive procedures like endovascular aneurysm repair (EVAR). The United States, specifically, sees more than 25,000 EVAR procedures annually, reflecting its dominant role in the global market. The increasing aging population in North America, with approximately 10 million people aged 65 and older affected by aortic aneurysms, drives demand for stent grafts. 

Europe

follows closely behind, contributing around 30% to the global market. Countries like Germany, the UK, and France are key players in Europe, where advanced healthcare systems and high incidence rates of aortic aneurysms fuel demand. In Europe, EVAR procedures make up about 65-70% of all aortic aneurysm treatments, with more than 15,000 procedures conducted annually. The European market benefits from similar advantages as North America, such as government-funded healthcare programs and widespread adoption of minimally invasive treatments. In countries with rapidly aging populations, such as Italy and Spain, there is a growing demand for stent grafts, with over 60% of patients being over the age of 65. 

Asia-Pacific

is experiencing rapid market growth, projected to expand by 7-10% annually. The region, which includes countries such as China, India, Japan, and Australia, is seeing an increase in the adoption of aortic stent grafts due to improvements in healthcare infrastructure and rising awareness of vascular diseases. In countries like China, where the number of patients diagnosed with aortic aneurysms has increased by 10-15% over the last decade, the demand for stent grafts is growing steadily. However, despite this growth, the region still lags behind North America and Europe in terms of adoption, with EVAR procedures currently accounting for only 15-20% of all aortic aneurysm treatments. 

Middle East & Africa

The Middle East & Africa market for Aortic Stent Grafts is growing steadily, supported by improving healthcare infrastructure and rising awareness about vascular diseases. The UAE and Saudi Arabia lead in market share due to the presence of advanced medical facilities and government initiatives promoting minimally invasive treatments. South Africa has also witnessed a surge in aortic aneurysm diagnosis and treatment, with an estimated 5,000 cases annually. In contrast, other African nations face challenges such as limited access to advanced medical treatments and lower affordability. 

LIST OF KEY Aortic Stent Grafts Market COMPANIES PROFILED

• Medtronic
• Cook Medical
• Cordis
• Gore Medical
• Lombard Medical
• Vascutek
• Johnson & Johnson
• Endologix
• W.L. Gore & Associates

Top Two Companies with Highest Share

• Medtronic: Holds approximately 35% of the global market share.
• Gore Medical: Holds approximately 20% of the global market share.

Investment Analysis And Opportunities

Investments in the Aortic Stent Grafts market have been increasing significantly, driven by advancements in research, manufacturing capabilities, and strategic collaborations. Global investment in vascular health research has surpassed $2 billion, with many stakeholders focused on improving the efficacy of stent grafts through continuous clinical trials. In particular, clinical trials are increasingly aiming to enhance the durability and flexibility of these devices, ensuring they can accommodate a wider range of patients and anatomical variations. Companies are also investing heavily in upgrading manufacturing facilities to support the growing demand for stent grafts. 

New Product Development

Innovation remains a key focus for the Aortic Stent Grafts market, with manufacturers striving to enhance the flexibility, durability, and adaptability of stent grafts. As the clinical need for personalized and effective aneurysm treatments grows, companies are introducing next-generation stent grafts designed to address a broader range of anatomies and patient conditions.

In 2023, Medtronic launched the Endurant"™ "Evo AAA Stent Graft System, which features an advanced fixation mechanism designed to improve the stability and durability of the graft in patients with complex abdominal aortic aneurysms (AAA). This system has received positive feedback from the clinical community for its performance and ease of deployment. Similarly, Gore Medical introduced the EXCLUDER"® "Conformable AAA Endoprosthesis, which is engineered to treat patients with difficult aortic anatomies, such as those with large or irregular aneurysms. T

Recent Developments by Manufacturers in the Aortic Stent Grafts Market (2023-2024)

• Medtronic launched an AI-driven imaging system to assist in the deployment of aortic stent grafts, improving procedural accuracy and reducing complications.

• Gore Medical received regulatory approval for its latest conformable stent graft in Europe, further expanding its product portfolio to address complex aortic aneurysms.

• Cook Medical expanded its production capacity with a new manufacturing facility in the U.S., ensuring the timely supply of aortic stent grafts to meet growing demand.
• Endologix initiated a clinical trial for a novel polymer-based aortic stent graft, which is expected to improve durability and reduce complications in high-risk patients.
• Lombard Medical secured funding for next-generation stent graft development, focusing on enhancing flexibility and ease of deployment.

Report Coverage of Aortic Stent Grafts Market

The Aortic Stent Grafts Market report provides a comprehensive analysis of market trends, regional insights, competitive landscape, and technological advancements. It includes a detailed examination of factors driving demand, such as the aging population, the increasing prevalence of aortic aneurysms, and healthcare investments. The report also covers key market players and their strategies, product portfolios, and recent developments, offering stakeholders valuable insights into the competitive environment. Challenges such as regulatory constraints, pricing pressures, and market barriers are thoroughly addressed. In addition, the report highlights investment opportunities, emerging technologies, and future growth prospects, equipping stakeholders with actionable insights to navigate the evolving market landscape.